MACH32 is a medical technology company based in Edmonton, dedicated to stopping people from bleeding to death; bleeding from traumatic injuries like car accidents, postpartum hemorrhage, or battlefield injuries. Trauma is responsible for 9% of deaths worldwide every year and the number one thing we can do to save lives following traumatic injury is stop bleeding. We are repurposing a clinically proven medication that decreases the risk of death due to bleeding by ~30%, yet less than 5% of eligible patients receive it due to the complexity of IV administration and making it simple to deliver. So simple, it can be delivered without medical training. Think “EpiPen” but for traumatic bleeding.
We are developing IMSAFE, an intramuscular autoinjector designed to administer Tranexamic Acid (TXA) quickly and effectively. Unlike establishing an IV, IMSAFE is fast and easy to use; it can be used by anyone, even without medical training. This makes TXA more accessible in pre-hospital environments resulting in improved survival rates for trauma patients. Our vision is for IMSAFE to be available to not only first responders like paramedics and police officers, but available for layperson use in first aid kits.
Our team at MACH32 is proud of the work that we’ve been able to accomplish on the IMSAFE auto injector over the last couple of years, highlights include:
- Prototype functional testing completed: The IMSAFE autoinjector has been thoroughly tested and has shown to outperform competitors in both speed and efficiency of delivery.
- Pharmacokinetic trial completed: Conducted by a military partner, the trial demonstrated that IMSAFE delivers TXA faster than the current standard of care (IV).
- User testing and market validation: Our first formal usability testing was conducted at NAIT’s Center for Advanced Medical Simulation. Since then, successful usability trials with military, EMS, fire, and police officers validated IMSAFE’s ease of use and functionality in real-world, high-stress environments.
- Patents filed: Patents have been filed for the device, drug formulation, and the combination, securing our intellectual property.
- Health economics study completed: A preliminary study conducted by the Institute of Health Economics determined that IMSAFE could generate between $6,000 and $13,000 in savings per patient for healthcare systems, emphasizing its economic and life-saving potential.
The work described above would not have been possible without non-dilutive grants from Alberta Innovates and NRC-IRAP. MACH32 is currently participating in the Boston Canadian Technology Accelerator Program as well as the Elevate Women’s Plus Program, which supports the development of female entrepreneurs. Our team is hyper focused on bringing IMSAFE to market. Some of our objectives over the next several months is to raise capital to accelerate development, including development of a proprietary TXA formulation, completion of pre-clinical studies and interacting with the FDA to confirm our regulatory strategy.
Learn more about us here:
YouTube: Mach 32 – MedTech Innovator 1 Minute Video – YouTube
Website: www.mach32.net
LinkedIn: https://www.linkedin.com/company/mach32
